Hong Cen

机构：Guangxi Medical University, Jiangxi Provincial Cancer Hospital, NARI Group (China), Tumor Hospital of Guangxi Medical University · ORCID：0000-0001-7233-5692

发表论文 37 篇 · 总被引 185 次 · h-index 7

代表论文

• Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002) (2021 · Journal of Hematology & Oncology · 被引 64)
• Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. (2024 · Journal of Clinical Oncology · 被引 17)
• Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials (2023 · Blood · 被引 14)
• Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy (2022 · Frontiers in Genetics · 被引 11)
• A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas (2023 · Blood · 被引 7)
• GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL). (2022 · Journal of Clinical Oncology · 被引 6)